Bausch Health launches second late-stage study for NOV03 for dry eye

 

• Bausch Health Companies (NYSE:BHC) and its global eye health business, Bausch + Lomb has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) to treat the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
• Enrollment of the first Phase 3 study is currently underway and has reached 85% of its enrollment goal.
• NOV03 is an investigational, water-free and preservative-free solution, based on patented EyeSol technology from Novaliq GmbH.
• https://seekingalpha.com/news/3639003-bausch-health-launches-second-late-stage-study-for-nov03-for-dry-eye-disease